A detailed history of Tower Research Capital LLC (Trc) transactions in Inhibrx, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 398 shares of INBX stock, worth $5,639. This represents 0.0% of its overall portfolio holdings.

Number of Shares
398
Previous 5,637 92.94%
Holding current value
$5,639
Previous $214,000 93.93%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$32.76 - $39.56 $171,629 - $207,254
-5,239 Reduced 92.94%
398 $13,000
Q4 2023

Feb 13, 2024

SELL
$14.5 - $38.0 $3,900 - $10,222
-269 Reduced 4.55%
5,637 $214,000
Q3 2023

Nov 14, 2023

BUY
$15.75 - $26.31 $54,668 - $91,322
3,471 Added 142.55%
5,906 $108,000
Q2 2023

Aug 14, 2023

SELL
$16.96 - $27.82 $66,364 - $108,859
-3,913 Reduced 61.64%
2,435 $63,000
Q1 2023

May 09, 2023

BUY
$18.45 - $27.14 $26,051 - $38,321
1,412 Added 28.61%
6,348 $120,000
Q4 2022

Feb 10, 2023

SELL
$20.18 - $33.33 $14,469 - $23,897
-717 Reduced 12.68%
4,936 $121,000
Q3 2022

Nov 10, 2022

BUY
$11.58 - $24.73 $12,911 - $27,573
1,115 Added 24.57%
5,653 $101,000
Q2 2022

Aug 15, 2022

BUY
$8.52 - $25.26 $27,076 - $80,276
3,178 Added 233.68%
4,538 $52,000
Q1 2022

May 12, 2022

SELL
$19.89 - $43.18 $16,071 - $34,889
-808 Reduced 37.27%
1,360 $30,000
Q4 2021

Feb 14, 2022

BUY
$26.75 - $46.02 $50,851 - $87,484
1,901 Added 711.99%
2,168 $95,000
Q3 2021

Nov 15, 2021

SELL
$25.18 - $37.81 $15,762 - $23,669
-626 Reduced 70.1%
267 $9,000
Q2 2021

Aug 16, 2021

SELL
$14.69 - $27.52 $4,333 - $8,118
-295 Reduced 24.83%
893 $25,000
Q1 2021

May 17, 2021

BUY
$16.27 - $41.26 $6,735 - $17,081
414 Added 53.49%
1,188 $24,000
Q4 2020

Feb 16, 2021

BUY
$15.96 - $50.0 $12,353 - $38,700
774 New
774 $26,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.